Neurocrine Biosciences (NBIX) and Catalyst Pharmaceuticals (CPRX)

Amgen broke out Tuesday from a cup without handle with 288.46 section point and is still inside purchasing range. Likewise remember that the latest example is a later-stage base, which makes it more hazardous to lay out another position or add offers to a current one.

The biotech organization revealed 6% profit development last quarter. Sales went up 4%.

Amgen stock procures the No. In the Medical-Biomed/Biotech industry group, 39 ranks among its peers. Neurocrine Biosciences (NBIX) and Catalyst Pharmaceuticals (CPRX) are also among the group’s highest-rated stocks. For more industry news, look at “Biotech And Drug Industry And Stock News.”

Leave a Comment